ArticleMolecular cancer2026
Micropeptide YG-6 encoded by exosomal LINC01123 derived from highly migratory ovarian cancer cells promotes tumor progression.
Article in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundIntercellular crosstalk plays a pivotal role in tumor progression and metastasis. Exosomes can package long non-coding RNAs (lncRNAs) to mediate extracellular communication. Although exosome research in various cancers has made remarkable progress, it remains unclear in ovarian cancer (OC) whether the cellular communication between OC cells with different metastatic potentials influences progression via exosomal-lncRNA. Besides, lncRNA can encode functional micropeptides, yet the association between OC and micropeptides encoded by exosomal-derived lncRNA has not been reported.
methodsOC cell-derived exosomes were characterized using transmission electron microscopy, nanoparticle tracking analysis, and WB. Exosomal lncRNA sequencing results of highly migratory OC cells (HMOs) and low migratory OC cells (LMOs) were analyzed, and LINC01123 was selected for further study. The effect of exosome LINC01123 on the function of LMOs was detected by the co-culture experiment. Bioinformatics prediction, mass spectrometry (MS), WB, and a series of functional experiments showed that LINC01123 encodes a small 59 aa peptide, named YG-6 (LINC01123 Yield peptide Gaining metastasis function: ORF no.6). Immunofluorescence, qPCR, WB, immunohistochemistry, and MS analysis were used to detect the endogenous expression of YG-6 in OC cells and tissues. The function of YG-6 in OC was investigated by detecting cell migration ability and observing tumor metastasis in nude mice. Mechanistically, the relationship between the YG-6 and ACTC1 in OC was verified by Co-Immunoprecipitation, WB, MS, immunofluorescence, and functional experiment.
resultsLINC01123 was significantly up-regulated in exosomes derived from HMOs and was readily internalized by LMOs, promoting their malignant behavior. Interestingly, LINC01123 encodes a small peptide composed of 59 amino acids, named YG-6, which exhibits endogenous high expression in OC cells and tissues. Functional experiments demonstrated that LINC01123 promotes tumor progression by encoding the peptide YG-6, rather than via an RNA-dependent mechanism. Furthermore, we identified ACTC1 as a binding protein of YG-6, which can synergistically activate the focal adhesion signaling pathway together with YG-6, thereby promoting the migration and adhesion of LMOs.
conclusionsOur findings not only demonstrate the YG-6 peptide encoded by LINC01123 as a potential prognostic biomarker for OC but also uncover a new mechanism of OC progression driven by YG-6 peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.